Analyzing Lucira Health (LHDXQ) and Its Competitors

Defense World ·  Apr 25, 2023 14:54

Lucira Health (NASDAQ:LHDXQ – Get Rating) is one of 41 publicly-traded companies in the "Diagnostic substances" industry, but how does it contrast to its peers? We will compare Lucira Health to similar businesses based on the strength of its dividends, analyst recommendations, institutional ownership, valuation, risk, profitability and earnings.

Analyst Recommendations

This is a summary of recent ratings for Lucira Health and its peers, as provided by MarketBeat.

Get Lucira Health alerts:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucira Health 0 0 0 0 N/A
Lucira Health Competitors 365 629 1235 19 2.40

As a group, "Diagnostic substances" companies have a potential upside of 33.93%. Given Lucira Health's peers higher possible upside, analysts plainly believe Lucira Health has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares Lucira Health and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Lucira Health $93.06 million -$64.83 million -0.03
Lucira Health Competitors $480.44 million $10.72 million -52.66

Lucira Health's peers have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

57.0% of Lucira Health shares are held by institutional investors. Comparatively, 46.6% of shares of all "Diagnostic substances" companies are held by institutional investors. 30.4% of Lucira Health shares are held by company insiders. Comparatively, 14.1% of shares of all "Diagnostic substances" companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


This table compares Lucira Health and its peers' net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lucira Health -67.54% -13.55% -8.47%
Lucira Health Competitors -802.63% -114.55% -27.76%

Risk and Volatility

Lucira Health has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Comparatively, Lucira Health's peers have a beta of 1.37, indicating that their average share price is 37% more volatile than the S&P 500.


Lucira Health beats its peers on 7 of the 10 factors compared.

About Lucira Health

(Get Rating)

Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.

Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment